New drug cocktail aims to shrink Hard-to-Treat adrenal tumors
NCT ID NCT06006013
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether combining cabozantinib (a drug that blocks tumor growth and blood vessel formation) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can shrink tumors in people with advanced adrenocortical carcinoma. The study enrolls 21 adults whose cancer has spread, is locally advanced, or cannot be surgically removed. Participants receive both drugs and are monitored for tumor response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib and pembrolizumab
What this could lead to
If it works, this could point toward a new treatment option for advanced adrenal cancer that has spread or cannot be removed by surgery.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENAL CORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital Midtown
RECRUITINGAtlanta, Georgia, 30308, United States
Contact
Contact Email: •••••@•••••
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••